Search results
Showing 1 to 15 of 20 results for age-related macular degeneration
This guideline covers diagnosing and managing age-related macular degeneration (AMD) in adults. It aims to improve the speed at which people are diagnosed and treated to prevent loss of sight.
Aflibercept solution for injection for treating wet age‑related macular degeneration (TA294)
Evidence-based recommendations on aflibercept solution for injection (Eylea) for treating wet age-related macular degeneration in adults.
Faricimab for treating wet age-related macular degeneration (TA800)
Evidence-based recommendations on faricimab (Vabysmo) for wet age-related macular degeneration in adults.
Brolucizumab for treating wet age-related macular degeneration (TA672)
Evidence-based recommendations on brolucizumab (Beovu) for treating wet age-related macular degeneration in adults.
Ranibizumab and pegaptanib for the treatment of age-related macular degeneration (TA155)
Evidence-based recommendations on ranibizumab (Lucentis) and pegaptanib (Macugen) for treating wet age-related macular oedema in adults.
This quality standard covers the diagnosis and management of cataracts, glaucoma and age-related macular degeneration (AMD) and the prevention of sight loss. It describes high-quality care in priority areas for improvement.
View quality statements for QS180Show all sections
Sections for QS180
- Quality statements
- Quality statement 1: Referral – chronic open angle glaucoma and related conditions
- Quality statement 2: Referral for cataract surgery
- Quality statement 3: Treatment – late age-related macular degeneration (wet active)
- Quality statement 4: Monitoring late age-related macular degeneration (wet active)
- Quality statement 5: Reassessment – chronic open angle glaucoma or related conditions
- Quality statement 6: Certificate of vision impairment
- Update information
Evidence-based recommendations on radiotherapy for age-related macular degeneration. This involves using radiation to destroy the new blood vessels, with the aim of slowing down sight loss.
View recommendations for IPG49Show all sections
Transpupillary thermotherapy for age-related macular degeneration (IPG58)
Evidence-based recommendations on transpupillary thermotherapy for age-related macular degeneration. This involves using a laser to heat and seal up the blood vessels that are causing the problems.
View recommendations for IPG58Show all sections
Limited macular translocation for wet age-related macular degeneration (IPG339)
Evidence-based recommendations on limited macular translocation for wet age related macular degeneration. This involves cutting and moving the macula on an a nearby healthier area of the retina.
Miniature lens system implantation for advanced age-related macular degeneration (IPG565)
Evidence-based recommendations on miniature lens system implantation for advanced age-related macular degeneration. This involves implanting an artificial lens system into 1 eye only.
Macular translocation with 360° retinotomy for wet age-related macular degeneration (IPG340)
Evidence-based recommendations on macular translocation with 360° retinotomy for wet age related macular degeneration. This involves cutting and moving the macula on to a nearby healthier area of the choroid layer.
Epiretinal brachytherapy for wet age-related macular degeneration (IPG415)
Evidence-based recommendations on epiretinal brachytherapy for wet age related macular degeneration. This involves using radiation therapy used to destroy the new blood vessels.
View recommendations for IPG415Show all sections
Sections for IPG415
Evidence-based recommendations on brolucizumab (Beovu) for diabetic macular oedema in adults.
Aflibercept for treating choroidal neovascularisation (TA486)
Evidence-based recommendations on aflibercept (Eylea) for treating choroidal neovascularisation in adults.
Evidence-based recommendations on ranibizumab (Lucentis) for treating diabetic macular oedema in adults.
View recommendations for TA274Show all sections